

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 8-K

FLEMINGTON PHARMACEUTICAL CORP

Form 8-K

October 03, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) OCTOBER 1, 2002  
-----

NOVADEL PHARMA INC.

-----  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE

000-23399

22-2407152

-----  
(STATE OR OTHER  
JURISDICTION OF  
FORMATION)

(COMMISSION  
FILE NUMBER)

(IRS EMPLOYER  
IDENTIFICATION NO.)

31 STATE HIGHWAY 12

FLEMINGTON, NJ

08822

-----  
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (908) 782-3431  
-----

FLEMINGTON PHARMACEUTICAL CORPORATION

-----  
(FORMER NAME OR FORMER ADDRESS, IF CHANGES SINCE LAST REPORT)

ITEM 5. OTHER EVENTS.  
-----

On October 1, 2002, Flemington Pharmaceutical Corporation, a Delaware corporation, changed its name to "Novadel Pharma Inc." (the "Company") by amending its Certificate of Incorporation. On October 3, 2002, the Company's trading symbol on the OTC Bulletin Board was changed to "NVDL" to reflect the change in the Company's name.

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 8-K

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA INFORMATION AND EXHIBITS.  
-----

(c) Exhibits

99 Press Release dated October 2, 2002.

ITEM 9. REGULATION FD DISCLOSURE.  
-----

Exhibit 99 hereto sets forth a press release issued by the Company to report the name change and additional information about the Company.

1

SIGNATURES  
-----

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly authorized and caused the undersigned to sign this Report on the Registrant's behalf.

NOVADEL PHARMA INC.

By:/s/Harry A. Dugger, III  
-----

Name: Harry A. Dugger, III  
Title: President and Chief Executive  
Officer

Dated: October 3, 2002

2